Propranolol-d7 (hydrochloride)

Propranolol-d7 (hydrochloride) is a deuterium labeled Propranolol hydrochloride. Propranolol hydrochloride is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol hydrochloride is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

Product Specifications

CAS Number

[1613439-56-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Neurological Disease; Cardiovascular Disease

Purity

98.47

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(COC1=C2C=CC=CC2=CC=C1)CNC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H].[H]Cl

Molecular Formula

C16H15D7ClNO2

Molecular Weight

302.85

Precautions

H302

References & Citations

[1]Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70 (5) :1575-84.|[2]Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69 (4) :669-73.|[3]Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.